On December 24, Shanghai Government unveiled the "Work Plan for Developing Medical Artificial Intelligence (2025–2027)" to advance the deep integration of artificial intelligence (AI) with clinical medicine and promote the application of vertical large models in diagnostic support for testing and inspection.

Pertussis is a highly contagious acute respiratory disease that can last for several months and often causes epidemics.

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.70 billion for the fourth quarter ended October 31, 2024, an increase of 0.8% reported and a decline of 0.3% core(1) compared to the fourth quarter of 2023.

With a large number of tumor-targeted drugs on the market, companion diagnosis is increasingly used in the process of tumor treatment. The results of using tissue samples for tumor companion diagnosis are more accurate than selecting plasma-free DNA (cell-free DNA, cfDNA).

Xcell Therapeutics is expanding the business scope of its exosome isolation and purification device, “EXODUS,” into the diagnostics market.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC) for the PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* test. This test is now the first and only FDA-approved companion diagnostic to aid in the assessment of HER2-positive status to identify BTC patients who are eligible for treatment with Jazz Pharmaceuticals' ZIIHERA® (zanidatamab-hrii).

Artificial intelligence continues to reshape healthcare, but a new study highlights the challenges of integrating AI tools into medical practice. ChatGPT-4, an AI chatbot developed by OpenAI, outperformed doctors in a diagnostic accuracy study, raising questions about how effectively physicians can use such technology.

Sheba Medical Center’s innovation arm, Accelerate, Redesign, and Collaborate (ARC), has partnered with Roche to advance the diagnosis and treatment of non-small cell lung cancer (NSCLC) by leveraging AI.

Li Li, commissioner of China's National Medical Products Administration (NMPA), led a delegation to Vietnam and Thailand from 11 to 15 November to enhance bilateral collaboration in pharmaceutical regulation. During the visit, Li signed memorandums of understanding (MoUs) with health authorities in both countries.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies.

Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has entered into a strategic co-marketing agreement with Agilent Technologies, a leading tools provider in the genomics sector. The agreement offers select customers the opportunity to access Tagomics’ and Agilent Technologies’ combined innovative offerings through an exclusive technology access program hosted out of Tagomics’ service lab in Cambridge.

Alveo Technologies, Inc. (Alveo), a leader in decentralized molecular diagnostics with its proprietary IntelliSense™ molecular detection technology, today announced that it received an agreement issued by the United States Centers for Disease Control and Prevention (CDC) on a competitive basis to develop a rapid, molecular, point of need diagnostic to detect and differentiate between Influenza A + B, and A/H5 in humans.